


PHARMACEUTICAL 2023



ALPINE IMMUNE SCIENCES INC. Rank 179 of 446





PHARMACEUTICAL 2023



ALPINE IMMUNE SCIENCES INC. Rank 179 of 446

The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 46% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 84% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	240,993
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	57,996
Liabilities, Non-Current	49,270
Other Assets	44,109
Other Compr. Net Income	-848
Other Expenses	2,806
Other Liabilities	0
Other Net Income	3,191
Other Revenues	30,064
Property and Equipment	1,584
Research and Development	70,243
Selling, General and Administrative Expense	17,968

Output Variable	Value in 1000 USD
Assets	286,686
Liabilities	107,266
Expenses	91,017
Revenues	30,064
Stockholders Equity	179,420
Net Income	-57,762
Comprehensive Net Income	-58,186
Economic Capital Ratio	127%

